Flex Pharma, Inc. (FLKS) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 105 transactions totaling $18.8M, demonstrating a bullish sentiment with $5.5M in net insider flow. The most recent transaction on Jan 30, 2019 involved a sale of 1,600,000 shares valued at $528.0K.
No significant insider buying has been recorded for FLKS in the recent period.
No significant insider selling has been recorded for FLKS in the recent period.
Based on recent SEC filings, insider sentiment for FLKS is bullish with an Insider Alignment Score of 65/100 and a net flow of $5.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Flex Pharma, Inc. (FLKS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading FLKS stock, having executed 105 transactions in the past 90 days. The most active insider is Christoph H. Westphal (Executive), who has made 86 transactions totaling $9.1M.
Get notified when executives and directors at FLKS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 30, 2019 | Inc. Boston Foundation, | Executive | Sale | 1,600,000 | $0.33 | $528.0K | Large |
| Jan 9, 2019 | Inc. Boston Foundation, | Executive | Sale | 337,000 | $0.37 | $124.7K | |
| Jan 8, 2019 | Inc. Boston Foundation, | Executive | Sale | 263,000 | $0.40 | $105.2K | |
| Dec 20, 2018 | H. Westphal Christoph | Executive | Gift | 2,200,000 | $N/A | $0 | |
| Nov 6, 2018 | H. Westphal Christoph | Executive | Gift | 858,300 | $N/A | $0 | |
| Oct 16, 2018 | H. Westphal Christoph | Executive | Sale | 3,212,861 | $0.92 | $3.0M | Large |
| Oct 16, 2018 | Ii, L.p. Longwood Fund | Executive | Sale | 3,212,861 | $0.92 | $3.0M | Large |
| Nov 8, 2016 | H. Westphal Christoph | Executive | Purchase | 7,000 | $7.31 | $51.2K | |
| Nov 7, 2016 | P. Mccabe John | Executive | Purchase | 1,650 | $6.01 | $9.9K | |
| Nov 7, 2016 | H. Westphal Christoph | Executive | Purchase | 8,870 | $5.70 | $50.6K | |
| Jun 23, 2016 | H. Westphal Christoph | Executive | Purchase | 2,700 | $11.28 | $30.5K | |
| Jun 22, 2016 | H. Westphal Christoph | Executive | Purchase | 2,900 | $11.03 | $32.0K | |
| Jun 21, 2016 | H. Westphal Christoph | Executive | Purchase | 2,800 | $11.07 | $31.0K | |
| Jun 20, 2016 | H. Westphal Christoph | Executive | Purchase | 3,000 | $11.37 | $34.1K | |
| Jun 17, 2016 | H. Westphal Christoph | Executive | Purchase | 3,000 | $10.98 | $32.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 91 | $12.1M | 64.5% |
Sale(S) | 5 | $6.7M | 35.5% |
Gift(G) | 2 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insiders at Flex Pharma, Inc. are accumulating shares at an accelerated pace. With 10 insiders making 105 transactions totaling $12.1M in purchases versus $6.7M in sales, the net buying activity of $5.5M signals strong executive confidence. Christoph H. Westphal (Executive) leads the buying activity with $9.1M in transactions across all time.